{"id":1083,"date":"2023-02-19T16:34:40","date_gmt":"2023-02-19T16:34:40","guid":{"rendered":"https:\/\/oncologytweetorials-ce.com\/?p=1083"},"modified":"2023-02-22T13:29:13","modified_gmt":"2023-02-22T13:29:13","slug":"lungcancer_esmoio22c","status":"publish","type":"post","link":"https:\/\/oncologytweetorials-ce.com\/lungcancer_esmoio22c\/","title":{"rendered":"Utilizing Immunohistochemistry Testing, Biomarkers, and Targeted Therapeutics to Optimize Outcomes in Patients with NSCLC"},"content":{"rendered":"\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">2) The faculty for this outstanding program were <a href=\"https:\/\/twitter.com\/peters_solange?ref_src=twsrc%5Etfw\">@peters_solange<\/a> (Chair) \ud83c\udde8\ud83c\udded, <a href=\"https:\/\/twitter.com\/HosseinBorghaei?ref_src=twsrc%5Etfw\">@HosseinBorghaei<\/a> \ud83c\uddfa\ud83c\uddf8, Natasha Leighl MD \ud83c\udde8\ud83c\udde6, and <a href=\"https:\/\/twitter.com\/dplanchard?ref_src=twsrc%5Etfw\">@dplanchard<\/a> \ud83c\uddeb\ud83c\uddf7. A truly international roster of experts in <a href=\"https:\/\/twitter.com\/hashtag\/oncology?src=hash&amp;ref_src=twsrc%5Etfw\">#oncology<\/a>!<br>Don&#39;t miss prior accredited courses in this space at <a href=\"https:\/\/t.co\/1GN3yvXUW6\">https:\/\/t.co\/1GN3yvXUW6<\/a>.<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1628379853354401794?ref_src=twsrc%5Etfw\">February 22, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">4) Our understanding and characterization of various subtypes of <a href=\"https:\/\/twitter.com\/hashtag\/LCSM?src=hash&amp;ref_src=twsrc%5Etfw\">#LCSM<\/a> adenocarcinoma continues to expand! This potentially allows for more targeted and safer therapy. Newer markers such as <a href=\"https:\/\/twitter.com\/hashtag\/CEACAM5?src=hash&amp;ref_src=twsrc%5Etfw\">#CEACAM5<\/a> are emerging, expanding treatment options ! <a href=\"https:\/\/t.co\/LRafGQ4mSO\">pic.twitter.com\/LRafGQ4mSO<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1628379857045397504?ref_src=twsrc%5Etfw\">February 22, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">6) <a href=\"https:\/\/twitter.com\/hashtag\/Platinum?src=hash&amp;ref_src=twsrc%5Etfw\">#Platinum<\/a>-based chemotherapy has historically been standard <a href=\"https:\/\/twitter.com\/hashtag\/1L?src=hash&amp;ref_src=twsrc%5Etfw\">#1L<\/a> for <a href=\"https:\/\/twitter.com\/hashtag\/mNSCLC?src=hash&amp;ref_src=twsrc%5Etfw\">#mNSCLC<\/a>, <br>BUT<br><br>\u27a1\ufe0f Responses only in 15\u201330%<br>\u27a1\ufe0f Relatively short interval until progression. <br>More recently, <a href=\"https:\/\/twitter.com\/hashtag\/immunotherapy?src=hash&amp;ref_src=twsrc%5Etfw\">#immunotherapy<\/a> has emerged as a promising alternative \u2714\ufe0f <a href=\"https:\/\/t.co\/buWVEKTlXv\">pic.twitter.com\/buWVEKTlXv<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1628379860690141189?ref_src=twsrc%5Etfw\">February 22, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">8) Immune therapies exploit the host immune system to monitor &amp; destroy cancer cells via the upregulation of key immune checkpoints; at present, <a href=\"https:\/\/twitter.com\/hashtag\/NSCLC?src=hash&amp;ref_src=twsrc%5Etfw\">#NSCLC<\/a> immunotherapy mainly refers to immune checkpoint inhibitors (<a href=\"https:\/\/twitter.com\/hashtag\/ICIs?src=hash&amp;ref_src=twsrc%5Etfw\">#ICIs<\/a>). <a href=\"https:\/\/twitter.com\/NCI?ref_src=twsrc%5Etfw\">@NCI<\/a> <a href=\"https:\/\/t.co\/9IpNpx7JE8\">pic.twitter.com\/9IpNpx7JE8<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1628379864934805505?ref_src=twsrc%5Etfw\">February 22, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">10) Currently, programmed death-ligand 1 (<a href=\"https:\/\/twitter.com\/hashtag\/PDL1?src=hash&amp;ref_src=twsrc%5Etfw\">#PDL1<\/a>) expression is the only clinically validated biomarker for selecting patients for tx with an <a href=\"https:\/\/twitter.com\/hashtag\/ICI?src=hash&amp;ref_src=twsrc%5Etfw\">#ICI<\/a>. <a href=\"https:\/\/t.co\/07HnKX73XQ\">pic.twitter.com\/07HnKX73XQ<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1628379869829554176?ref_src=twsrc%5Etfw\">February 22, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">12) Let\u2019s discuss treatment <a href=\"https:\/\/twitter.com\/hashtag\/selection?src=hash&amp;ref_src=twsrc%5Etfw\">#selection<\/a>! What level of PD-L1 expression is currently preferred for use of single agent immunotherapy?<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1628379874183327746?ref_src=twsrc%5Etfw\">February 22, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">14) Recently, we have seen major progress from targeting <a href=\"https:\/\/twitter.com\/hashtag\/NSCLC?src=hash&amp;ref_src=twsrc%5Etfw\">#NSCLC<\/a> beyond chemotx (&amp; PD-L1) w\/signal transduction in oncogene addicted NSCLC:<br>\ud83d\udc49Small molecule inhibitors, antibodies, ADCs<br>\ud83d\udc49EGFR (inc exon20), BRAF, MET, KRAS, ERBB2<br>\ud83d\udc49ALK, ROS1, NTRK, RET, (NRG1\u2026)<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1628379877811318786?ref_src=twsrc%5Etfw\">February 22, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">15b) Epidermal growth factor receptor-targeting tyrosine kinase inhibitors (<a href=\"https:\/\/twitter.com\/hashtag\/EGFR?src=hash&amp;ref_src=twsrc%5Etfw\">#EGFR<\/a> <a href=\"https:\/\/twitter.com\/hashtag\/TKIs?src=hash&amp;ref_src=twsrc%5Etfw\">#TKIs<\/a>) are the standard of care for patients with EGFR-mutated <a href=\"https:\/\/twitter.com\/hashtag\/LCSM?src=hash&amp;ref_src=twsrc%5Etfw\">#LCSM<\/a>. While EGFR TKIs have initially high response rates, resistance constitute a major challenge to longitudinal tx. <a href=\"https:\/\/t.co\/AS2B5VP2dX\">pic.twitter.com\/AS2B5VP2dX<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1628379882810929154?ref_src=twsrc%5Etfw\">February 22, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">17) Smaller proportions of patients are impacted <a href=\"https:\/\/twitter.com\/hashtag\/mNSCLC?src=hash&amp;ref_src=twsrc%5Etfw\">#mNSCLC<\/a> driven by <a href=\"https:\/\/twitter.com\/hashtag\/ROS1?src=hash&amp;ref_src=twsrc%5Etfw\">#ROS1<\/a> fusions, <a href=\"https:\/\/twitter.com\/hashtag\/BRAF?src=hash&amp;ref_src=twsrc%5Etfw\">#BRAF<\/a> mutations, <a href=\"https:\/\/twitter.com\/hashtag\/NTRK?src=hash&amp;ref_src=twsrc%5Etfw\">#NTRK<\/a> fusions, and <a href=\"https:\/\/twitter.com\/hashtag\/RET?src=hash&amp;ref_src=twsrc%5Etfw\">#RET<\/a> fusions, where we have witnessed good progress in treatments: <a href=\"https:\/\/t.co\/HDv6C9NCex\">pic.twitter.com\/HDv6C9NCex<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1628379886829068288?ref_src=twsrc%5Etfw\">February 22, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">19a) We mentioned Anti-<a href=\"https:\/\/twitter.com\/hashtag\/CEACAM5?src=hash&amp;ref_src=twsrc%5Etfw\">#CEACAM5<\/a> therapy above . . . CEACAM5 is a <a href=\"https:\/\/twitter.com\/hashtag\/glycoprotein?src=hash&amp;ref_src=twsrc%5Etfw\">#glycoprotein<\/a> implicated in a variety of oncogenic activities, and was first recognized as a marker for <a href=\"https:\/\/twitter.com\/hashtag\/coloncancer?src=hash&amp;ref_src=twsrc%5Etfw\">#coloncancer<\/a>. <a href=\"https:\/\/t.co\/sWwr6Th5MW\">pic.twitter.com\/sWwr6Th5MW<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1628379890918600704?ref_src=twsrc%5Etfw\">February 22, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">19c) <br>\ud83e\udec1 Most frequent limiting dose toxicity was <a href=\"https:\/\/twitter.com\/hashtag\/keratopathy?src=hash&amp;ref_src=twsrc%5Etfw\">#keratopathy<\/a><br>Ongoing trials include Ph 2 studies with tusamitamab ravtansine in combination w\/ <a href=\"https:\/\/twitter.com\/hashtag\/pembrolizumab?src=hash&amp;ref_src=twsrc%5Etfw\">#pembrolizumab<\/a> (NCT04524689), or <a href=\"https:\/\/twitter.com\/hashtag\/ramucirumab?src=hash&amp;ref_src=twsrc%5Etfw\">#ramucirumab<\/a> (NCT04394624), and a phase III trial that compares tusamitamab ravtansine w\/ <a href=\"https:\/\/twitter.com\/hashtag\/docetaxel?src=hash&amp;ref_src=twsrc%5Etfw\">#docetaxel<\/a><\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1628379895637200899?ref_src=twsrc%5Etfw\">February 22, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<blockquote class=\"twitter-tweet\"><p lang=\"en\" dir=\"ltr\">21) Thank you for following this \ud83e\uddf5! You can now claim 0.5hr \ud83c\udd93CE\/<a href=\"https:\/\/twitter.com\/hashtag\/CME?src=hash&amp;ref_src=twsrc%5Etfw\">#CME<\/a> by pointing your \ud83d\uddb1\ufe0f to <a href=\"https:\/\/t.co\/S0Oj90c92w\">https:\/\/t.co\/S0Oj90c92w<\/a>. And please follow us here at <a href=\"https:\/\/twitter.com\/onc_ce?ref_src=twsrc%5Etfw\">@onc_ce<\/a> for more expert education in current topics in <a href=\"https:\/\/twitter.com\/hashtag\/oncology?src=hash&amp;ref_src=twsrc%5Etfw\">#oncology<\/a>, delivered wholly on Twitter!<br>\ud83d\ude4f<a href=\"https:\/\/twitter.com\/ADesaiMD?ref_src=twsrc%5Etfw\">@ADesaiMD<\/a> for editorial support<\/p>&mdash; @onc_ce (@onc_ce) <a href=\"https:\/\/twitter.com\/onc_ce\/status\/1628379899109994499?ref_src=twsrc%5Etfw\">February 22, 2023<\/a><\/blockquote> <script async src=\"https:\/\/platform.twitter.com\/widgets.js\" charset=\"utf-8\"><\/script>\n\n\n\n<iframe id=\"JotFormIFrame-230495109000141\" title=\"lungcancer_esmoio22c | Oncology CE 2023new\" onload=\"window.parent.scrollTo(0,0)\" allowtransparency=\"true\" allowfullscreen=\"true\" allow=\"geolocation; microphone; camera\" src=\"https:\/\/form.jotform.com\/230495109000141\" frameborder=\"0\" style=\"min-width:100%;max-width:100%;height:1539px;border:none;\" scrolling=\"no\">\n    <\/iframe>\n    <script type=\"text\/javascript\">\n    var ifr = document.getElementById(\"JotFormIFrame-230495109000141\");\n    if (ifr) {\n      var src = ifr.src;\n      var iframeParams = [];\n      if (window.location.href && window.location.href.indexOf(\"?\") > -1) {\n        iframeParams = iframeParams.concat(window.location.href.substr(window.location.href.indexOf(\"?\") + 1).split('&'));\n      }\n      if (src && src.indexOf(\"?\") > -1) {\n        iframeParams = iframeParams.concat(src.substr(src.indexOf(\"?\") + 1).split(\"&\"));\n        src = src.substr(0, src.indexOf(\"?\"))\n      }\n      iframeParams.push(\"isIframeEmbed=1\");\n      ifr.src = src + \"?\" + iframeParams.join('&');\n    }\n    window.handleIFrameMessage = function(e) {\n      if (typeof e.data === 'object') { return; }\n      var args = e.data.split(\":\");\n      if (args.length > 2) { iframe = document.getElementById(\"JotFormIFrame-\" + args[(args.length - 1)]); } else { iframe = document.getElementById(\"JotFormIFrame\"); }\n      if (!iframe) { return; }\n      switch (args[0]) {\n        case \"scrollIntoView\":\n          iframe.scrollIntoView();\n          break;\n        case \"setHeight\":\n          iframe.style.height = args[1] + \"px\";\n          if (!isNaN(args[1]) && parseInt(iframe.style.minHeight) > parseInt(args[1])) {\n            iframe.style.minHeight = args[1] + \"px\";\n          }\n          break;\n        case \"collapseErrorPage\":\n          if (iframe.clientHeight > window.innerHeight) {\n            iframe.style.height = window.innerHeight + \"px\";\n          }\n          break;\n        case \"reloadPage\":\n          window.location.reload();\n          break;\n        case \"loadScript\":\n          if( !window.isPermitted(e.origin, ['jotform.com', 'jotform.pro']) ) { break; }\n          var src = args[1];\n          if (args.length > 3) {\n              src = args[1] + ':' + args[2];\n          }\n          var script = document.createElement('script');\n          script.src = src;\n          script.type = 'text\/javascript';\n          document.body.appendChild(script);\n          break;\n        case \"exitFullscreen\":\n          if      (window.document.exitFullscreen)        window.document.exitFullscreen();\n          else if (window.document.mozCancelFullScreen)   window.document.mozCancelFullScreen();\n          else if (window.document.mozCancelFullscreen)   window.document.mozCancelFullScreen();\n          else if (window.document.webkitExitFullscreen)  window.document.webkitExitFullscreen();\n          else if (window.document.msExitFullscreen)      window.document.msExitFullscreen();\n          break;\n      }\n      var isJotForm = (e.origin.indexOf(\"jotform\") > -1) ? true : false;\n      if(isJotForm && \"contentWindow\" in iframe && \"postMessage\" in iframe.contentWindow) {\n        var urls = {\"docurl\":encodeURIComponent(document.URL),\"referrer\":encodeURIComponent(document.referrer)};\n        iframe.contentWindow.postMessage(JSON.stringify({\"type\":\"urls\",\"value\":urls}), \"*\");\n      }\n    };\n    window.isPermitted = function(originUrl, whitelisted_domains) {\n      var url = document.createElement('a');\n      url.href = originUrl;\n      var hostname = url.hostname;\n      var result = false;\n      if( typeof hostname !== 'undefined' ) {\n        whitelisted_domains.forEach(function(element) {\n            if( hostname.slice((-1 * element.length - 1)) === '.'.concat(element) ||  hostname === element ) {\n                result = true;\n            }\n        });\n        return result;\n      }\n    };\n    if (window.addEventListener) {\n      window.addEventListener(\"message\", handleIFrameMessage, false);\n    } else if (window.attachEvent) {\n      window.attachEvent(\"onmessage\", handleIFrameMessage);\n    }\n    <\/script>\n","protected":false},"excerpt":{"rendered":"<p>2) The faculty for this outstanding program were @peters_solange (Chair) \ud83c\udde8\ud83c\udded, @HosseinBorghaei \ud83c\uddfa\ud83c\uddf8, Natasha Leighl MD \ud83c\udde8\ud83c\udde6, and @dplanchard \ud83c\uddeb\ud83c\uddf7. A truly international roster of experts in #oncology!Don&#39;t miss prior accredited courses in this space at https:\/\/t.co\/1GN3yvXUW6. &mdash; @onc_ce (@onc_ce) February 22, 2023 4) Our understanding and characterization of various subtypes of #LCSM adenocarcinoma continues [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","_mi_skip_tracking":false,"footnotes":""},"categories":[22],"tags":[],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/posts\/1083"}],"collection":[{"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/comments?post=1083"}],"version-history":[{"count":2,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/posts\/1083\/revisions"}],"predecessor-version":[{"id":1086,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/posts\/1083\/revisions\/1086"}],"wp:attachment":[{"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/media?parent=1083"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/categories?post=1083"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oncologytweetorials-ce.com\/wp-json\/wp\/v2\/tags?post=1083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}